TR201900148T4 - Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. - Google Patents
Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. Download PDFInfo
- Publication number
- TR201900148T4 TR201900148T4 TR2019/00148T TR201900148T TR201900148T4 TR 201900148 T4 TR201900148 T4 TR 201900148T4 TR 2019/00148 T TR2019/00148 T TR 2019/00148T TR 201900148 T TR201900148 T TR 201900148T TR 201900148 T4 TR201900148 T4 TR 201900148T4
- Authority
- TR
- Turkey
- Prior art keywords
- diamino
- against cancer
- agents against
- novel agents
- quinoline substituted
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- NKXSJFUIFJMXED-UHFFFAOYSA-N quinoline-2,4-diamine Chemical group C1=CC=CC2=NC(N)=CC(N)=C21 NKXSJFUIFJMXED-UHFFFAOYSA-N 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical group C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Bu buluş yeni 2-primer amino-4-sekonder amino-kinolin türevlerine, bunların imalatına, bunları içeren farmasötik bileşimlere ve bunların ilaçlar olarak kullanımına ilişkindir. Bu buluşun etken bileşikleri proliferatif neoplastik ve neoplastik olmayan hastalıkların tedavisi ve önlenmesi için yararlıdır.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073325P | 2014-10-31 | 2014-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900148T4 true TR201900148T4 (tr) | 2019-02-21 |
Family
ID=55404745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00148T TR201900148T4 (tr) | 2014-10-31 | 2015-10-26 | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10722505B2 (tr) |
| EP (1) | EP3212629B1 (tr) |
| JP (1) | JP6588546B2 (tr) |
| KR (1) | KR102548547B1 (tr) |
| CN (1) | CN107148416B (tr) |
| AU (1) | AU2015338844B2 (tr) |
| CA (1) | CA2965262C (tr) |
| CL (1) | CL2017001073A1 (tr) |
| CO (1) | CO2017007325A2 (tr) |
| CR (1) | CR20170177A (tr) |
| CY (1) | CY1121326T1 (tr) |
| DK (1) | DK3212629T3 (tr) |
| DO (1) | DOP2017000107A (tr) |
| EA (1) | EA037119B1 (tr) |
| EC (1) | ECSP17026748A (tr) |
| ES (1) | ES2707125T3 (tr) |
| GE (1) | GEP20207108B (tr) |
| HR (1) | HRP20190107T1 (tr) |
| IL (1) | IL251775B (tr) |
| LT (1) | LT3212629T (tr) |
| MA (1) | MA40875B1 (tr) |
| MY (1) | MY193740A (tr) |
| NI (1) | NI201700052A (tr) |
| PE (1) | PE20191142A1 (tr) |
| PH (1) | PH12017500810A1 (tr) |
| PL (1) | PL3212629T3 (tr) |
| PT (1) | PT3212629T (tr) |
| RS (1) | RS58328B1 (tr) |
| SG (1) | SG11201703479SA (tr) |
| SI (1) | SI3212629T1 (tr) |
| TN (1) | TN2017000168A1 (tr) |
| TR (1) | TR201900148T4 (tr) |
| UA (1) | UA122062C2 (tr) |
| WO (1) | WO2016067112A1 (tr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452465B1 (en) * | 2016-05-04 | 2020-11-04 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2022033459A1 (zh) * | 2020-08-10 | 2022-02-17 | 萧乃文 | 双非癌药物用于制备治疗癌症的医药组合物的用途 |
| CN112375081B (zh) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用 |
| CN112876673B (zh) * | 2021-01-25 | 2021-12-24 | 山东大学 | 一种pH响应性纳米共聚物载体及其制备方法和应用 |
| EP4349336A1 (en) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers |
| EP4520396A1 (en) | 2023-09-05 | 2025-03-12 | Genoscience Pharma | Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| WO2004052862A1 (ja) * | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| JP2006519846A (ja) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| ES2790419T3 (es) * | 2013-01-15 | 2020-10-27 | Incyte Holdings Corp | Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM |
| KR20150132192A (ko) * | 2013-03-18 | 2015-11-25 | 제노사이언스 파마 | 신규한 항암제로서의 퀴놀린 유도체 |
-
2015
- 2015-10-26 ES ES15837091T patent/ES2707125T3/es active Active
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/lt unknown
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/ko active Active
- 2015-10-26 UA UAA201705278A patent/UA122062C2/uk unknown
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 CA CA2965262A patent/CA2965262C/en active Active
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
- 2015-10-26 PT PT15837091T patent/PT3212629T/pt unknown
- 2015-10-26 PL PL15837091T patent/PL3212629T3/pl unknown
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/tr unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/en active Active
- 2015-10-26 MA MA40875A patent/MA40875B1/fr unknown
- 2015-10-26 CR CR20170177A patent/CR20170177A/es unknown
- 2015-10-26 RS RS20190110A patent/RS58328B1/sr unknown
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 HR HRP20190107TT patent/HRP20190107T1/hr unknown
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/en not_active Ceased
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/ja active Active
- 2015-10-26 SI SI201530566T patent/SI3212629T1/sl unknown
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/zh active Active
- 2015-10-26 EA EA201790949A patent/EA037119B1/ru unknown
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/es unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/es unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/es unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/es unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/es unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/es unknown
-
2019
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201900148T4 (tr) | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. | |
| MX2015013396A (es) | Derivados de quinolinas como nuevos agentes contra el cancer. | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
| TW201613901A (en) | New compounds | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2015008957A (es) | Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1). | |
| EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
| TW201613864A (en) | Novel compounds | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| TR201908265T4 (tr) | Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |